Legal & General Group Plc Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Posted by George Bondi on Aug 30th, 2026

Legal & General Group Plc acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 323,087 shares of the biopharmaceutical company’s stock, valued at approximately $25,288,000. Legal & General Group Plc owned 0.28% of Halozyme Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC grew its position in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the period. Larson Financial Group LLC increased its stake in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the last quarter. MidFirst Bank bought a new stake in Halozyme Therapeutics during the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $28,000. Finally, Quantbot Technologies LP bought a new stake in Halozyme Therapeutics during the second quarter worth $30,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 64,103 shares of company stock valued at $5,226,496 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on HALO shares. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, TD Cowen increased their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Check Out Our Latest Stock Analysis on Halozyme Therapeutics

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $105.35 on Friday. The company has a market capitalization of $11.96 billion, a PE ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The firm has a fifty day simple moving average of $87.01 and a 200 day simple moving average of $74.78. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $109.66.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.